The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Efficacy and toxicity profile of eribulin mesylate for metastatic breast cancer (MBC) patients (pts) in the routine clinic: A French observational study.
Anne Patsouris
No relevant relationships to disclose
Benjamin Linot
No relevant relationships to disclose
Marie Robert
No relevant relationships to disclose
Carole Gourmelon
No relevant relationships to disclose
Mario Campone
Consultant or Advisory Role - Novartis; SERVIER
Honoraria - Novartis; SERVIER
Angelique Brunot
No relevant relationships to disclose
Claudia Lefeuvre-Plesse
Honoraria - Eisai
Jerome Martin
No relevant relationships to disclose
Adele Marquis
No relevant relationships to disclose
Hugues Pierre Bourgeois
No relevant relationships to disclose
Mickael Som
No relevant relationships to disclose
Herve Desclos
Honoraria - Eisai
Olivier Tredan
Research Funding - Eisai